Alliance Pharma plc is a speciality pharmaceutical company. The principal activity of the Company is the acquisition, marketing and distribution of pharmaceutical products. The Company promotes products in two areas of specialization, Dermatology and Secondary Care. Its dermatology product portfolio includes Acnisal, Hydromol, Pentrax, Alphaderm, Isotretinoin, Permitabs, Aquadrate, Meted, Quinoderm, Atarax, Naseptin, Timodine, Dermamist and Occlusal. The Company�s product portfolio in the secondary care includes Absorbagel, ImmuCyst, Naturcare, Clearway, La Vera, SkinSafe, Deogel, Lift, Ultracleanse, Gelclair and Lift plus. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.